451 related articles for article (PubMed ID: 23864113)
1. Rosiglitazone inhibits insulin-like growth factor‑1-induced polycystic kidney disease cell growth and p70S6 kinase activation.
Liu C; Zhang Y; Yuan L; Fu L; Mei C
Mol Med Rep; 2013 Sep; 8(3):861-4. PubMed ID: 23864113
[TBL] [Abstract][Full Text] [Related]
2. Thiazolidinediones inhibit insulin-like growth factor-i-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity.
He G; Sung YM; Digiovanni J; Fischer SM
Cancer Res; 2006 Feb; 66(3):1873-8. PubMed ID: 16452250
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone inhibits transforming growth factor-β1 mediated fibrogenesis in ADPKD cyst-lining epithelial cells.
Liu Y; Dai B; Xu C; Fu L; Hua Z; Mei C
PLoS One; 2011; 6(12):e28915. PubMed ID: 22174924
[TBL] [Abstract][Full Text] [Related]
4. Concomitant use of rapamycin and rosiglitazone delays the progression of polycystic kidney disease in Han:SPRD rats: a study of the mechanism of action.
Liu C; Li H; Gao X; Yang M; Yuan L; Fu L; Wang X; Mei C
Am J Physiol Renal Physiol; 2018 May; 314(5):F844-F854. PubMed ID: 26911848
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells.
Liu Y; Dai B; Fu L; Jia J; Mei C
Basic Clin Pharmacol Toxicol; 2010 Jun; 106(6):523-30. PubMed ID: 20210794
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
Sommer M; Wolf G
Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
[TBL] [Abstract][Full Text] [Related]
7. Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway.
Higashi Y; Holder K; Delafontaine P
J Biol Chem; 2010 Nov; 285(47):36361-8. PubMed ID: 20843793
[TBL] [Abstract][Full Text] [Related]
8. A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling.
Yuan Y; Zhang A; Huang S; Ding G; Chen R
Am J Physiol Renal Physiol; 2011 Feb; 300(2):F393-402. PubMed ID: 21123490
[TBL] [Abstract][Full Text] [Related]
9. p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels.
Park JY; Schutzer WE; Lindsley JN; Bagby SP; Oyama TT; Anderson S; Weiss RH
BMC Nephrol; 2007 Aug; 8():12. PubMed ID: 17714589
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats.
Dai B; Liu Y; Mei C; Fu L; Xiong X; Zhang Y; Shen X; Hua Z
Clin Sci (Lond); 2010 Jul; 119(8):323-33. PubMed ID: 20507283
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling.
Osman I; Segar L
Biochem Pharmacol; 2016 Feb; 101():54-70. PubMed ID: 26643070
[TBL] [Abstract][Full Text] [Related]
13. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
14. Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation.
Nishio S; Hatano M; Nagata M; Horie S; Koike T; Tokuhisa T; Mochizuki T
J Clin Invest; 2005 Apr; 115(4):910-8. PubMed ID: 15761494
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor-β inhibits cystogenesis in human autosomal dominant polycystic kidney epithelial cells.
Elberg D; Jayaraman S; Turman MA; Elberg G
Exp Cell Res; 2012 Aug; 318(13):1508-16. PubMed ID: 22504005
[TBL] [Abstract][Full Text] [Related]
16. Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF/Raf/MAPK/ERK signaling pathway.
Xu T; Wang NS; Fu LL; Ye CY; Yu SQ; Mei CL
Mol Biol Rep; 2012 Jul; 39(7):7743-53. PubMed ID: 22415852
[TBL] [Abstract][Full Text] [Related]
17. Phosphatidylinositol 3-kinase (PI-3K)/Akt but not PI-3K/p70 S6 kinase signaling mediates IGF-1-promoted lens epithelial cell survival.
Chandrasekher G; Sailaja D
Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3577-88. PubMed ID: 15452065
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone suppresses human lung carcinoma cell growth through PPARgamma-dependent and PPARgamma-independent signal pathways.
Han S; Roman J
Mol Cancer Ther; 2006 Feb; 5(2):430-7. PubMed ID: 16505118
[TBL] [Abstract][Full Text] [Related]
19. DH9, a novel PPARγ agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of β-catenin signaling.
Liu M; Fu L; Liu C; Xiong X; Gao X; Xiao M; Cai H; Hu H; Wang X; Mei C
Invest New Drugs; 2010 Dec; 28(6):783-90. PubMed ID: 19756375
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
